Encorafenib Patent Expiration
Encorafenib is Used for treating metastatic non-small cell lung cancer, metastatic colorectal cancer, and melanoma with BRAF mutations. It was first introduced by Array Biopharma Inc
Encorafenib Patents
Given below is the list of patents protecting Encorafenib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Braftovi | US9474754 | Pharmaceutical combinations comprising a B-RAF inhibitor, and EGFR inhibitor and optionally a PI3K-α inhibitor | Aug 05, 2033 | Array Biopharma Inc |
| Braftovi | US10258622 | Method of treating colorectal cancer by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)pheny1)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl) carbamate | Nov 21, 2032 | Array Biopharma Inc |
| Braftovi | US9387208 | Pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate | Nov 21, 2032 | Array Biopharma Inc |
| Braftovi | US9763941 | Method of treating melanoma by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate | Nov 21, 2032 | Array Biopharma Inc |
| Braftovi | US9314464 | Compounds and compositions as protein kinase inhibitors | Jul 04, 2031 | Array Biopharma Inc |
| Braftovi | US8501758 | Compounds and compositions as protein kinase inhibitors | Mar 04, 2031 | Array Biopharma Inc |
| Braftovi | US10005761 | Compounds and compositions as protein kinase inhibitors | Aug 27, 2030 | Array Biopharma Inc |
| Braftovi | US8501758 | Compounds and compositions as protein kinase inhibitors | Aug 27, 2030 | Array Biopharma Inc |
| Braftovi | US9593099 | Compounds and compositions as protein kinase inhibitors | Aug 27, 2030 | Array Biopharma Inc |
| Braftovi | US9593100 | Compounds and compositions as protein kinase inhibitors | Aug 27, 2030 | Array Biopharma Inc |
| Braftovi | US9850229 | Compounds and compositions as protein kinase inhibitors | Aug 27, 2030 | Array Biopharma Inc |
| Braftovi | US9850230 | Compounds and compositions as protein kinase inhibitors | Aug 27, 2030 | Array Biopharma Inc |
| Braftovi | USRE49556 | Compounds and compositions as protein kinase inhibitors | Feb 27, 2030 | Array Biopharma Inc |
| Braftovi | US8541575 | 3,4-diarylpyrazoles as protein kinase inhibitors | Feb 26, 2030 | Array Biopharma Inc |
| Braftovi | US8946250 | 3,4-diarylpyrazoles as protein kinase inhibitors | Jul 23, 2029 | Array Biopharma Inc |
Encorafenib's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Encorafenib:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
